Medpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) P/E ratio
As of 5 November 2026, Medpace Holdings, Inc. (MEDP) trades at a P/E ratio of 34.6×. Over the past ten years it has ranged from 0.0× (September 2016) to 96.2× (December 2016); the current reading is higher than 58% of that period. That is in line with the Diagnostics & Research industry median of 34.5× and above the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 35.9× | 40.99% |
| FY2024 | 25.4× | (23.42%) |
| FY2023 | 33.2× | 21.36% |
| FY2022 | 27.4× | (36.37%) |
| FY2021 | 43.0× | 25.76% |
| FY2020 | 34.2× | 13.52% |
| FY2019 | 30.1× | 19.54% |
| FY2018 | 25.2× | (32.14%) |
| FY2017 | 37.1× | (58.87%) |
| FY2016 | 90.3× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 34.0× | 11.63% |
| Jun 2026 | 30.5× | 2.99% |
| Mar 2026 | 29.6× | (17.56%) |
| Dec 2025 | 35.9× | 2.26% |
| 40 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GH Guardant Health, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 25.0× |
| QGEN QIAGEN N.V. compare | 26.1× |
| LH Labcorp Holdings Inc. compare | 29.5× |
| ICLR ICON PLC compare | 34.5× |
| MEDP Medpace Holdings, Inc. | 34.6× |
| ILMN Illumina, Inc. compare | 35.6× |
| RVTY Revvity Inc. compare | 71.9× |
| CRL Charles River Laboratories International, Inc. compare | 300× |
| Diagnostics & Research industry median | 34.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement